FDA chief’s resignation widens a leadership gap at the nation’s health department

Dr. Marty Makary stepped down as head of the U.S. Food and Drug Administration (FDA) on Tuesday, leaving the agency without a permanent leader amid ongoing reviews of ultra-processed foods, antidepressants, and COVID-19 vaccines. His resignation deepens a leadership crisis at the Department of Health and Human Services (HHS), where multiple key roles—including the surgeon general and CDC director—remain unfilled or held by acting officials. The FDA’s vacancy follows a pattern of instability under Health Secretary Robert F. Kennedy Jr., with critics citing a lack of scientific expertise and recent cuts. The agency is grappling with Kennedy’s push to scrutinize ingredients in food, medicines, and vaccines, while balancing anti-regulatory pressures from traditional Republicans. Deputy Commissioner Kyle Diamantas, overseeing the ultra-processed foods definition, has called the task ‘really hard,’ highlighting the complexity of the challenge. HHS has faced criticism for its handling of public health issues, with trust in federal agencies declining in recent years. Experts warn that leadership gaps could undermine the agency’s ability to respond effectively during health crises, such as the recent hantavirus outbreak. The department did not immediately respond to requests for comment. Makary’s departure leaves the FDA’s vaccine chief position vacant for the second time in a year, further straining its capacity to address pressing health priorities. The agency’s future leadership will need to navigate Kennedy’s policies while addressing partisan and corporate interests. With no Senate-confirmed surgeon general and interim leadership at critical agencies, the HHS faces mounting scrutiny over its ability to function during public health emergencies.